### **USER-CENTERED** DEVICE CONNECTIVITY

In this article, Mark Tunkel, Partner and Head of Business Development, and Carolyn Rose, Director of Research and Strategy, both of Insight Product Development, discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.

The methods available to pharmaceutical companies and device suppliers to support the patient journey and experience are offering more possibilities than ever before. Traditionally, the focus of the patient experience has been on optimising the "administration task" as outlined in the instructions for use, with an emphasis on the reduction of use error risk. However, as clinical outcomes are increasingly driving payer decision making, developers are expanding their efforts to support the patient journey more broadly. This is being achieved through enhanced methods of training, value-added packaging and longitudinal methods of engagement that span from the onset of a disease state through various life stages.

In addition to these measures, virtually every developer in the branded and generic space is formulating some variation of a digital health strategy that features device connectivity for parenteral and inhalation devices. Initially, these strategies focus on the development of add-ons or accessories that are compatible with a commercially available device and provide users with device performance feedback - like when an autoinjector is ready to inject or when an injection is complete. They can also provide error correction and other means of feedback to help eliminate use errors. The Smart Pilot accessory from Ypsomed (Burgdorf, Switzerland) is an example of a device providing this level of functionality.

"There has been convergence within the drug delivery ecosystem, where all aspects of managing a disease state are integrated through connectivity." These devices are very effective at helping to mitigate potential use error with more mature devices. These devices also feature a mobile application that can collect and curate use information for potential integration into a patient's health plan.

There has also been convergence within the drug delivery ecosystem, where all aspects of managing a disease state are integrated through connectivity. A good example of this is the Bigfoot Biomedical connected diabetes management ecosystem, which is a comprehensive solution that integrates the Abbott Diabetes Freestyle Libre sensor-based glucose management technology into Bigfoot insulin pens and pumps. Abbott has also partnered with Novo Nordisk in a similar arrangement. All these ecosystems are reliant upon sensor technology and mobile applications that act as the primary interface for all the component pieces. Similar to the add-ons scenario, these ecosystems are addressing known workflows and device component constraints.

In the future, it is reasonable to expect that novel and platform device ecosystems will begin to integrate connected technology into the device architecture itself. While there are regulatory issues to address, patient experiences that include connectivity and analytics supported by Amazon Web Services or Google cloud platforms hold immense promise to deliver better outcomes and experiences for patients and health systems.

Achieving success will require the use of a robust digital health strategy. A critical tool in helping developers formulate a user-driven strategy is a thorough mapping of the patient journey – to develop an intimate understanding of foundational user needs so that the entire journey is considered at the earliest stages of development.

A comprehensive understanding of the user enables the team to determine how these needs can be most effectively



Mark Tunkel Partner and Head of Business Development T: +1 773 828 4050 E: mtunkel@insightpd.com



Carolyn Rose Director of Research & Strategy

**Insight Product Development** 4660 N Ravenswood Ave Chicago IL 60640 United States

www.insightpd.com

addressed, whether through the device, a software capability or with an interplay between the two augmented by other assets. This approach helps ensure developed technologies are not only meeting actual market needs; they're doing so in an optimal way - eliminating potential redundancies and conflicts that are inevitable when developing device and software in isolation.

Understanding, characterising and prioritising user needs is best achieved through applied ethnography (Figure 1) which consists of a combination of interviews and observation within the context of use. This method can yield a deep, longitudinal understanding of the patient journey (Figure 2) - from diagnosis to treatment selection, onboarding and ongoing use. With an emphasis on system touchpoints like education/training materials, secondary packaging and device interaction, the patient journey can then be leveraged as a critical early-stage decision-making tool.



Figure 1: Applied ethnography helps developers learn about the context of use and the patient journey in self-administration as the foundation for a connected device strategy.

Like drug discovery, this type of research should be started as early as possible in the development process - user needs are the cornerstone in defining the path forward. While some believe considerations surrounding the patient and device should

be suspended until drug attributes are clearly defined, this approach can lead to decision making on device development or selection that can take a developer too far down a development path to make meaningful changes.

#### PRE - DIAGNOSIS: And Their Implications to Delivery Device Design atient will enter into this state unaware The c that they have a disease. Most will suffer discomfort and be **confused** as to why they feel LAPSE IN THERAPY: the way they do. Some will seek medical A patient discontinues therapy for a variety of reasons. Sometimes early successes lead a patient to **abandon their treatment**, thinking that they have been "cured". Others may choose to end the tedium of their therapies due to the constant reminders they provide that they have a disease. The patient typically labose whereas others will be in denial until attentio symptoms advance to a point whi ical intervention is no longer optional. PATIENT DEGRADES: Through aging and the onset of co-morbidities, a patient's health will enter into a state of decline. At this time, the a disease. The patient typically to a point where their condition degrades to a more serious state. INITIAL DIAGNOSIS: a delivery system is even more critical to the patient's adherence. The ent must remain capable of using the cer as their motor, sensory, and hitive skills become increasingly nt seeks medical treatment, the **root** cause will be diagnosed. For some, this will be received with relief, as they know that being introduced to a treatment for their disease will result impaired. in an improved state of wellness. Others will result respond with feelings of shock and depression. These kinds of attitudes can greatly impair the likelihood of attorneys. likelihe od of adherence. PATIENT LIVES BETTER LIFE: the patient a positive delivery experience and effective support managing their disease, they will en enter managing their disease, they will enter into a state of loyalty to their delivery system and the company that provides it to them. This is further reinforced when that solution is successfully evolved over the long term as a well-thought-out EARLY TREATMENT AND ACCLIMATION: nt's early experience with medical A pat pipeline of innovation. A patient's early experience with medical therapy is very influential in determining the therapy's future success. The device the patient must learn to interact with should provide positive experiences that quickly acclimate them to their new realities and ir chances for adherent behavior. GETTING COMFORTABLE: Once accumated, the patient can become more demanding of their drug delivery experience. Comfortable with the understanding that they have a Comfortable with the understanding that they have a disease that they know how to manage, the patient now judges the experience of their regimen across new criteria, including expediency, comfort, convenience, and feedback. Many will start to actively seek alternatives to solutions that do not satisfy them.

Figure 2: The output from ethnography is a patient journey map that identifies opportunities for improving user experience or mitigating risk, including by using connected solutions.

#### Key Milestones Along the Patient Journey

"User needs should be characterised as soon as there is a known target patient population."

While usability testing activities are well understood when it comes to device selection and are critical at this stage, discovery research is a fundamentally different type of activity that seeks to define and understand user needs rather than help ensure they are met. User needs should be characterised as soon as there is a known target patient population – to most effectively drive the development of solutions covering the device, connectivity, mobile applications, data analytics and enhanced training that address the whole of the patient journey.

Ultimately, this information can be synthesised into a development road map. This consists of mapping identified needs with corresponding device and supporting element opportunities and capabilities. The road map can then be used to guide early mapping of the ideal envisioned patient and healthcare professional journey, and the process of exploring solutions that best meet the needs at each phase of the journey while enabling the team to consider solutions more holistically.

This is particularly important when determining where the integration of connectivity and data analytics can meaningfully support the experience. The road map also becomes the foundation for later requirements definition for the device, the mobile application and any other clinical interface required, ensuring that requirements stem from user needs, rather than known technical capabilities and limitations. The benefits of taking a user-needs approach in a connectivity strategy include:

- Helps developers ensure that all elements of a device strategy for a new drug product effectively address user needs optimally and holistically
- Provides early guidance on device selection (for platform devices) or organic device development requirements as well as gaps that need to be addressed by packaging, instructions for use, training and areas where connectivity can be impactful
- Identifies potential areas of user-based risk that may be present in clinical trials and in market so they can be mitigated as early as possible in development
- Works as the basis for developing a data analytics strategy that harnesses the insight into what elements of disease state management are most meaningful and worth of measurement for a particular application.

Ultimately, this approach drives efficiency in development as both commercial and research and development teams can address key portions of the strategy proactively to ensure all meaningful aspects of the patient journey or healthcare provider experience are enabled to support the ideal envisioned care model – and not used as a mitigation to a substandard experience or risk.

This will also benefit either novel or platform devices with connectivity features as a means of commercial differentiation, particularly in biosimilar or generic applications where multiple entrants may be using similar (or identical) devices.

#### ABOUT THE COMPANY

Insight Product Development is a design innovation consultancy focused on the medical device and drug delivery sectors since 1988. Capabilities include human factors engineering, design research, industrial design, engineering and prototyping. Insight supports its clients' device strategy across novel and platform devices. The company has expertise in contextual research and human factors driven understanding of the patient journey as well as design and development of autoinjectors, wearable injectors and inhalation devices across multiple chronic disease states.

# ABOUT THE AUTHORS

Mark Tunkel is a Partner and Director of Business Development at Insight Product Development. With more than 20 years of global business development experience and a deep understanding of the marketplace challenges and trends impacting the pharmaceutical industry, Mr Tunkel has advised many of the world's leading companies on their product development and innovation strategies with an emphasis on driving realisation and the most favourable business outcomes.

**Carolyn Rose** is the Director of Research and Strategy at Insight Product Development. With 18 years as a design researcher, she has consulted with hundreds of clients generating meaningful research insights and defining actionable strategic opportunities. Over the last 10 years at Insight, Ms Rose has led the research team to better understand the behaviours, expectations and motivations of patients and clinicians, as well as the environments, attitudes and trends that shape them.

## ON drugDELIVERY SUBSCRIBE TODAY! PRINT SUBSCRIPTION £99/YR + POSTAGE PDF SUBSCRIPTION IS ALWAYS FREE www.ondrugdelivery.com